ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer
- 1 June 1994
- journal article
- clinical trial
- Published by Elsevier in Cancer Letters
- Vol. 81 (2), 137-144
- https://doi.org/10.1016/0304-3835(94)90194-5
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Heregulin induces tyrosine phosphorylation of HER4/p180erbB4Nature, 1993
- A current view of tamoxifen for the treatment and prevention of breast cancerBritish Journal of Pharmacology, 1993
- Estrogen receptor mutations in breast cancerJournal of Cellular Biochemistry, 1993
- Role of estrogen receptor variants in the development of hormone resistance in breast cancerClinical Biochemistry, 1992
- The case for clinical trials of tamoxifen for prevention of breast cancerThe Lancet, 1992
- Isolation of the NeuHER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cellsCell, 1992
- Tamoxifen up-regulates c-erbB-2 expression in oestrogen-responsive breast cancer cells in vitroEuropean Journal Of Cancer, 1992
- Estrogen suppression of erbB2 expression is associated with increased growth rate of ZR‐75‐1 human breast cancer cells in vitro and in nude miceInternational Journal of Cancer, 1991
- Statistical evaluation of cell kinetic data from DNA flow cytometry (FCM) by the EM algorithmCytometry, 1989
- Amplification of a Novel v- erb B-Related Gene in a Human Mammary CarcinomaScience, 1985